Merck Approaches $10 Billion Acquisition of Verona Pharma
Merck is acquiring UK-based Verona Pharma for $10 billion to expand its respiratory treatment portfolio and diversify revenue sources beyond its blockbuster cancer drug Keytruda, with Verona's inhalable COPD treatment Ohtuvayre playing a key role.